Publication

GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity

Cell Reports 112466, 2023 [online ahead of print]. Falk S, Petersen J, Svendsen C, Romero-Leguizamón CR, Jørgensen SH, Krauth N, Ludwig MQ, Lundø K, Roostalu U, Skovbjerg G, Gurskov Nielsen DA, Ejdrup AL, Pers TH, Dmytriyeva O, Hecksher-Sørensen J, Gether U, Kohlmeier KA, Clemmensen C

Share this page

Resource Library

Related resources

The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice

Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides

Investigating intestinal glucagon after Roux-en-Y gastric bypass surgery

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650